Influence of serotype, cell type, tissue composition, and time after inoculation on gene expression in recombinant adeno-associated viral vector-transduced equine joint tissues

American Journal of Veterinary Research

Volumn 73, Issue 8, 2012, Pages 1178-1185

  Mason, Jeffrey B ^a   Vandenberghe, Luk H ^b,c   Xiao, Ru ^b,d   Wilson, James M ^b   Richardson, Dean W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Ocular Genomics Institute   (United States)

^d SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; RECOMBINANT ADENOVIRUS VECTOR 2; RECOMBINANT ADENOVIRUS VECTOR 5; RECOMBINANT ADENOVIRUS VECTOR 6.2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM TRANSDUCTION; CARTILAGE CELL; CELL TYPE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HORSE; MESENCHYMAL STROMA CELL; MONOLAYER CULTURE; NONHUMAN; OSTEOARTHRITIS; SEROTYPE; SYNOVIOCYTE;

ANIMALS; CELLS, CULTURED; DEPENDOVIRUS; GENE EXPRESSION REGULATION, VIRAL; GENETIC THERAPY; GENETIC VECTORS; HORSE DISEASES; HORSES; JOINTS; OSTEOARTHRITIS; SEROTYPING; STIFLE; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES;

EQUIDAE;

EID: 84865623679     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.8.1178     Document Type: Article

References (38)

1. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001;60:91-97.
2. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981-1000.
3. Sutton S, Clutterbuck A, Harris P, et al. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet J 2009;179:10-24.
4. Martel-Pelletier J, Alaaeddine N, Pelletier J-P. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999;4:D694-D703.
5. Dawson J, Linsell L, Zondervan K, et al. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology 2004;43:497-504.
6. Fraenkel L, Bogardus ST, Concato J, et al. Treatment options in knee osteoarthritis-the patient's perspective. Arch Intern Med 2004;164:1299-1304.
7. Walker-Bone K, Javaid K, Arden N, et al. Regular review-medical management of osteoarthritis. BMJ 2000;321:936-940.
8. Hunter DJ, Felson DT. Osteoarthritis. BMJ 2006;332:639B-642B.
9. Rossdale PD, Hopes R, Digby NJW. Epidemiological study of wastage among racehorses. 1982 and 1983. Vet Rec 1985;116:66-69.
10. Wilsher S, Allen WR, Wood JLN. Factors associated with failure of Thoroughbred horses to train and race. Equine Vet J 2006;38:113-118.
11. Evans CH, Ghivizzani SC, Robbins PD. Progress and prospects: genetic treatments for disorders of bones and joints. Gene Ther 2009;16:944-952.
12. Mease PJ, Wei N, Fudman EJ, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 study. J Rheumatol 2010;37:692-703.
13. Evans CH, Gouze E, Gouze JN, et al. Gene therapeutic approaches-transfer in vivo. Adv Drug Deliv Rev 2006;58:243-258.
14. Saraf A, Mikos AG. Gene delivery strategies for cartilage tissue engineering. Adv Drug Deliv Rev 2006;58:592-603.
15. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 2003;3:545-565.
16. Cottard V, Valvason C, Falgarone G, et al. Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes. J Clin Immunol 2004;24:162-169.
17. Hung GL, Galealauri J, Mueller GM, et al. Suppression of intraarticular responses to interlukin-1 by transfer of the interlukin-1 receptor antagonist gene to synovium. Gene Ther 1994;1:64-69.
18. Khoury M, Bigey P, Louis-Plence P, et al. A comparative study on intra-articular versus systemic gene electrotransfer in experimental arthritis. J Gene Med 2006;8:1027-1036.
19. Gouze E, Gouze JN, Palmer GD, et al. Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases. Mol Ther 2007;15:1114-1120.
20. Pan RY, Xiao X, Chen SL, et al. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. J Virol 1999;73:3410-3417.
21. Novotny JE, Turka CM, Jeong C, et al. Biomechanical and magnetic resonance characteristics of a cartilage-like equivalent generated in a suspension culture. Tissue Eng 2006;12:2755-2764.
22. Frean SP, Lees P. Effects of polysulfated glycosaminoglycan and hyaluronan on prostaglandin E2 production by cultured equine synoviocytes. Am J Vet Res 2000;61:499-505.
23. Giovannini S, Brehm W, Mainil-Varlet P, et al. Multilineage differentiation potential of equine blood-derived fibroblast-like cells. Differentiation 2008;76:118-129.
24. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-2232.
25. Auricchio A, Hildinger M, O'Connor E, et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001;12:71-76.
26. Hildinger M, Auricchio A, Gao G, et al. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001;75:6199-6203.
27. Gao GP, Alvira MR, Wang LL, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99:11854-11859.
28. Goodrich LR, Choi VW, Carbone BAD, et al. Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. Hum Gene Ther 2009;20:1697-1702.
29. Santangelo KS, Baker SA, Nuovo G, et al. Detectable reporter gene expression following transduction of adenovirus and adeno-associated virus serotype 2 vectors within full-thickness osteoarthritic and unaffected canine cartilage in vitro and unaffected guinea pig cartilage in vivo. J Orthop Res 2010;28:149-155.
30. Sumer EU, Schaller S, Sondergaard BC, et al. Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers 2006;11:485-506.
31. Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998;72:309-319.
32. Vandenberghe LH, Breous E, Nam HJ, et al. Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther 2009;16:1416-1428.
33. Wu ZJ, Miller E, Agbandje-McKenna M, et al. Alpha 2,3 and alpha 2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 2006;80:9093-9103.
34. Vandenberghe LH, Wilson JM. AAV as an immunogen. Curr Gene Ther 2007;7:325-333.
35. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001;75:6615-6624.
36. Kern A, Schmidt K, Leder C, et al. Identification of a heparinbinding motif on adeno-associated virus type 2 capsids. J Virol 2003;77:11072-11081.
37. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998;72:1438-1445.
38. Walters RW, Yi SMP, Keshavjee S, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001;276:20610-20616.